Neuroleptic malignant syndrome during zuclopenthixol therapy in X-linked cerebral adrenoleukodystrophy

M.E. Rubio-Gozalbo; D.A. van Waardenburg; Ph. Forget; L.J.M. Spaapen; A. Verrips; P.C.A.J. Vroomen

doi:10.1023/A:1012480130445

Neuroleptic malignant syndrome during zuclopenthixol therapy in X-linked cerebral adrenoleukodystrophy

M.E. Rubio-Gozalbo^*, D.A. van Waardenburg, Ph. Forget, L.J.M. Spaapen, A. Verrips, P.C.A.J. Vroomen

^*Corresponding author for this work

NUTRIM School of Nutrition and Translational Research in Metabolism

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Neuroleptic malignant syndrome during zuclopenthixol therapy in X-linked cerebral adrenoleukodystrophy.

Rubio-Gonzalbo ME, van Waardenburg DA, Forget PP, Spaapen LJ, Verrips A, Vroomen PC.

Department of Paediatrics, University Hospital Maastricht, The Netherlands. mrub@skin.azm.nl

An 8 year-old boy with X-ALD under treatment with simvastatin developed a severe adverse reaction when the dose of his other medication, zuclopenthixol was increased. Both drugs were withdrawn after a diagnosis of neuroleptic malignant syndrome was made

Original language	English
Pages (from-to)	605-606
Number of pages	2
Journal	Journal of Inherited Metabolic Disease
Volume	24
Issue number	5
DOIs	https://doi.org/10.1023/A:1012480130445
Publication status	Published - 1 Jan 2001

Access to Document

10.1023/A:1012480130445

Cite this

@article{6f1eb8db959940be9dc79a0fd9e106ec,

title = "Neuroleptic malignant syndrome during zuclopenthixol therapy in X-linked cerebral adrenoleukodystrophy",

abstract = "Neuroleptic malignant syndrome during zuclopenthixol therapy in X-linked cerebral adrenoleukodystrophy.Rubio-Gonzalbo ME, van Waardenburg DA, Forget PP, Spaapen LJ, Verrips A, Vroomen PC.Department of Paediatrics, University Hospital Maastricht, The Netherlands. mrub@skin.azm.nlAn 8 year-old boy with X-ALD under treatment with simvastatin developed a severe adverse reaction when the dose of his other medication, zuclopenthixol was increased. Both drugs were withdrawn after a diagnosis of neuroleptic malignant syndrome was made",

author = "M.E. Rubio-Gozalbo and {van Waardenburg}, D.A. and Ph. Forget and L.J.M. Spaapen and A. Verrips and P.C.A.J. Vroomen",

year = "2001",

month = jan,

day = "1",

doi = "10.1023/A:1012480130445",

language = "English",

volume = "24",

pages = "605--606",

journal = "Journal of Inherited Metabolic Disease",

issn = "0141-8955",

publisher = "Wiley",

number = "5",

}

TY - JOUR

T1 - Neuroleptic malignant syndrome during zuclopenthixol therapy in X-linked cerebral adrenoleukodystrophy

AU - Rubio-Gozalbo, M.E.

AU - van Waardenburg, D.A.

AU - Forget, Ph.

AU - Spaapen, L.J.M.

AU - Verrips, A.

AU - Vroomen, P.C.A.J.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Neuroleptic malignant syndrome during zuclopenthixol therapy in X-linked cerebral adrenoleukodystrophy.Rubio-Gonzalbo ME, van Waardenburg DA, Forget PP, Spaapen LJ, Verrips A, Vroomen PC.Department of Paediatrics, University Hospital Maastricht, The Netherlands. mrub@skin.azm.nlAn 8 year-old boy with X-ALD under treatment with simvastatin developed a severe adverse reaction when the dose of his other medication, zuclopenthixol was increased. Both drugs were withdrawn after a diagnosis of neuroleptic malignant syndrome was made

AB - Neuroleptic malignant syndrome during zuclopenthixol therapy in X-linked cerebral adrenoleukodystrophy.Rubio-Gonzalbo ME, van Waardenburg DA, Forget PP, Spaapen LJ, Verrips A, Vroomen PC.Department of Paediatrics, University Hospital Maastricht, The Netherlands. mrub@skin.azm.nlAn 8 year-old boy with X-ALD under treatment with simvastatin developed a severe adverse reaction when the dose of his other medication, zuclopenthixol was increased. Both drugs were withdrawn after a diagnosis of neuroleptic malignant syndrome was made

U2 - 10.1023/A:1012480130445

DO - 10.1023/A:1012480130445

M3 - Article

SN - 0141-8955

VL - 24

SP - 605

EP - 606

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

IS - 5

ER -